Literature DB >> 26468525

The Missing Link in Epstein-Barr Virus Immune Evasion: the BDLF3 Gene Induces Ubiquitination and Downregulation of Major Histocompatibility Complex Class I (MHC-I) and MHC-II.

Laura L Quinn1, Luke R Williams1, Claire White1, Calum Forrest1, Jianmin Zuo2, Martin Rowe1.   

Abstract

UNLABELLED: The ability of Epstein-Barr virus (EBV) to spread and persist in human populations relies on a balance between host immune responses and EBV immune evasion. CD8(+) cells specific for EBV late lytic cycle antigens show poor recognition of target cells compared to immediate early and early antigen-specific CD8(+) cells. This phenomenon is due in part to the early EBV protein BILF1, whose immunosuppressive activity increases with lytic cycle progression. However, published data suggest the existence of a hitherto unidentified immune evasion protein further enhancing protection against late EBV antigen-specific CD8(+) cells. We have now identified the late lytic BDLF3 gene as the missing link accounting for efficient evasion during the late lytic cycle. Interestingly, BDLF3 also contributes to evasion of CD4(+) cell responses to EBV. We report that BDLF3 downregulates expression of surface major histocompatibility complex (MHC) class I and class II molecules in the absence of any effect upon other surface molecules screened, including CD54 (ICAM-1) and CD71 (transferrin receptor). BDLF3 both enhanced internalization of surface MHC molecules and reduced the rate of their appearance at the cell surface. The reduced expression of surface MHC molecules correlated with functional protection against CD8(+) and CD4(+) T cell recognition. The molecular mechanism was identified as BDLF3-induced ubiquitination of MHC molecules and their subsequent downregulation in a proteasome-dependent manner. IMPORTANCE: Immune evasion is a necessary feature of viruses that establish lifelong persistent infections in the face of strong immune responses. EBV is an important human pathogen whose immune evasion mechanisms are only partly understood. Of the EBV immune evasion mechanisms identified to date, none could explain why CD8(+) T cell responses to late lytic cycle genes are so infrequent and, when present, recognize lytically infected target cells so poorly relative to CD8(+) T cells specific for early lytic cycle antigens. The present work identifies an additional immune evasion protein, BDLF3, that is expressed late in the lytic cycle and impairs CD8(+) T cell recognition by targeting cell surface MHC class I molecules for ubiquitination and proteasome-dependent downregulation. Interestingly, BDLF3 also targets MHC class II molecules to impair CD4(+) T cell recognition. BDLF3 is therefore a rare example of a viral protein that impairs both the MHC class I and class II antigen-presenting pathways.
Copyright © 2015, American Society for Microbiology. All Rights Reserved.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 26468525      PMCID: PMC4702578          DOI: 10.1128/JVI.02183-15

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  48 in total

1.  Major histocompatibility complex class I molecules are down-regulated at the cell surface by the K5 protein encoded by Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8.

Authors:  Muzammel Haque; Keiji Ueda; Kazushi Nakano; Yuko Hirata; Carlo Parravicini; Mario Corbellino; Koichi Yamanishi
Journal:  J Gen Virol       Date:  2001-05       Impact factor: 3.891

2.  Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins.

Authors:  S Ishido; C Wang; B S Lee; G B Cohen; J U Jung
Journal:  J Virol       Date:  2000-06       Impact factor: 5.103

3.  Downregulation of major histocompatibility complex class I by human ubiquitin ligases related to viral immune evasion proteins.

Authors:  Eric Bartee; Mandana Mansouri; Bianca T Hovey Nerenberg; Kristine Gouveia; Klaus Früh
Journal:  J Virol       Date:  2004-02       Impact factor: 5.103

4.  Interference with T cell receptor-HLA-DR interactions by Epstein-Barr virus gp42 results in reduced T helper cell recognition.

Authors:  Maaike E Ressing; Daphne van Leeuwen; Frank A W Verreck; Raquel Gomez; Bianca Heemskerk; Mireille Toebes; Maureen M Mullen; Theodore S Jardetzky; Richard Longnecker; Marco W Schilham; Tom H M Ottenhoff; Jacques Neefjes; Ton N Schumacher; Lindsey M Hutt-Fletcher; Emmanuel J H J Wiertz
Journal:  Proc Natl Acad Sci U S A       Date:  2003-09-22       Impact factor: 11.205

5.  Kaposi's sarcoma-associated herpesvirus-encoded viral IRF3 modulates major histocompatibility complex class II (MHC-II) antigen presentation through MHC-II transactivator-dependent and -independent mechanisms: implications for oncogenesis.

Authors:  Jianmin Zuo; Andrew D Hislop; Carol S Leung; Shereen Sabbah; Martin Rowe
Journal:  J Virol       Date:  2013-02-28       Impact factor: 5.103

6.  Spontaneous release of a factor with properties of T cell growth factor from a continuous line of primate tumor T cells.

Authors:  H Rabin; R F Hopkins; F W Ruscetti; R H Neubauer; R L Brown; T G Kawakami
Journal:  J Immunol       Date:  1981-11       Impact factor: 5.422

7.  Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysis.

Authors:  C J Barnstable; W F Bodmer; G Brown; G Galfre; C Milstein; A F Williams; A Ziegler
Journal:  Cell       Date:  1978-05       Impact factor: 41.582

8.  Establishment in continuous culture of a new type of lymphocyte from a "Burkitt like" malignant lymphoma (line D.G.-75).

Authors:  H Ben-Bassat; N Goldblum; S Mitrani; T Goldblum; J M Yoffey; M M Cohen; Z Bentwich; B Ramot; E Klein; G Klein
Journal:  Int J Cancer       Date:  1977-01       Impact factor: 7.396

9.  Surface antigens of human melanoma cells defined by monoclonal antibodies. I. Biochemical characterization of two antigens found on cell lines and fresh tumors of diverse tissue origin.

Authors:  J P Johnson; M Demmer-Dieckmann; T Meo; M R Hadam; G Riethmüller
Journal:  Eur J Immunol       Date:  1981-10       Impact factor: 5.532

10.  Differentiation-associated expression of the Epstein-Barr virus BZLF1 transactivator protein in oral hairy leukoplakia.

Authors:  L S Young; R Lau; M Rowe; G Niedobitek; G Packham; F Shanahan; D T Rowe; D Greenspan; J S Greenspan; A B Rickinson; P J Farrell
Journal:  J Virol       Date:  1991-06       Impact factor: 6.549

View more
  29 in total

1.  The Obligate Intracellular Bacterium Orientia tsutsugamushi Targets NLRC5 To Modulate the Major Histocompatibility Complex Class I Pathway.

Authors:  Kyle G Rodino; Haley E Adcox; Rebecca K Martin; Vaidehi Patel; Daniel H Conrad; Jason A Carlyon
Journal:  Infect Immun       Date:  2019-02-21       Impact factor: 3.441

2.  Human Cytomegalovirus Decreases Major Histocompatibility Complex Class II by Regulating Class II Transactivator Transcript Levels in a Myeloid Cell Line.

Authors:  Praneet K Sandhu; Nicholas J Buchkovich
Journal:  J Virol       Date:  2020-03-17       Impact factor: 5.103

Review 3.  The Immune Response to Epstein Barr Virus and Implications for Posttransplant Lymphoproliferative Disorder.

Authors:  Olivia M Martinez; Sheri M Krams
Journal:  Transplantation       Date:  2017-09       Impact factor: 4.939

Review 4.  The lytic phase of Epstein-Barr virus plays an important role in tumorigenesis.

Authors:  Yue Liang; Yan Zhang; Bing Luo
Journal:  Virus Genes       Date:  2022-10-15       Impact factor: 2.198

Review 5.  Epstein-Barr virus: Biology and clinical disease.

Authors:  Blossom Damania; Shannon C Kenney; Nancy Raab-Traub
Journal:  Cell       Date:  2022-09-15       Impact factor: 66.850

6.  Four Decades of Prophylactic EBV Vaccine Research: A Systematic Review and Historical Perspective.

Authors:  Gabriela M Escalante; Lorraine Z Mutsvunguma; Murali Muniraju; Esther Rodriguez; Javier Gordon Ogembo
Journal:  Front Immunol       Date:  2022-04-14       Impact factor: 8.786

7.  Epstein-Barr virus microRNAs reduce immune surveillance by virus-specific CD8+ T cells.

Authors:  Manuel Albanese; Takanobu Tagawa; Mickaël Bouvet; Liridona Maliqi; Dominik Lutter; Jonathan Hoser; Maximilian Hastreiter; Mitch Hayes; Bill Sugden; Larissa Martin; Andreas Moosmann; Wolfgang Hammerschmidt
Journal:  Proc Natl Acad Sci U S A       Date:  2016-10-03       Impact factor: 11.205

Review 8.  Giving CD4+ T cells the slip: viral interference with MHC class II-restricted antigen processing and presentation.

Authors:  Katherine S Forsyth; Laurence C Eisenlohr
Journal:  Curr Opin Immunol       Date:  2016-04-24       Impact factor: 7.486

Review 9.  Epstein-Barr virus-related post-transplant lymphoproliferative disease (EBV-PTLD) in the setting of allogeneic stem cell transplantation: a comprehensive review from pathogenesis to forthcoming treatment modalities.

Authors:  Rama Al Hamed; Abdul Hamid Bazarbachi; Mohamad Mohty
Journal:  Bone Marrow Transplant       Date:  2019-05-14       Impact factor: 5.483

10.  Epstein-Barr Virus and the Human Leukocyte Antigen Complex.

Authors:  Qingxue Li; Jeffrey I Cohen
Journal:  Curr Clin Microbiol Rep       Date:  2019-07-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.